Molecular pathological approaches to human tumor immunology

Pathology International

Volumn 59, Issue 4, 2009, Pages 205-217

  Sato, Noriyuki ^a   Hirohashi, Yoshihiko ^a   Tsukahara, Tomohide ^a   Kikuchi, Tomoki ^a   Sahara, Hiroeki ^b   Kamiguchi, Kenjiro ^a   Ichimiya, Shingo ^a   Tamura, Yasuaki ^a   Torigoe, Toshihiko ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AZABU UNIVERSITY   (Japan)

Author keywords

Antigenic peptide; Cross presentation; Epigenetics; Heat shock protein; Human leukocyte antigen; T cell; Tumor immunology; Tumor immunotherapy

Indexed keywords

ALANYLTYROSYLALANYLCYSTEINYLASPARAGINYLTHREONYLSERYLTHREONYLLEUCINE; ALANYLTYROSYLARGINYLPROLYLVALYLSERYLARGINYLASPARAGINYLISOLEUCINE; ALPHA INTERFERON; ARGINYLTYROSYLALANYLMETHIONYLTHREONYLVALYLTRYPTOPHYLTYROSYLPHENYLALANINE; ASPARAGINYLMETHIONYLVALYLGLUTAMYLGLYCYLTHREONYLALANYLTYROSYLLEUCINE; BASILIXIMAB; CANCER VACCINE; CYSTEINYLTHREONYLALANYLCYSTEINYLARGINYLTRYPTOPHYLLYSYLLYSYLALANYLCYSTEINYLGLUTAMINYLARGININE; FREUND ADJUVANT; GLUTAMINYLTYROSYLPHENYLALANYLLYSYLLYSYLISOLEUCYLPROLYLISOLEUCYLLEUCINE; GLYCOPROTEIN GP 100; GLYCYLTYROSYLASPARTYLGLUTAMINYLISOLEUCYLMETHIONYLPROLYLLYSYLISOLEUCINE; GLYCYLTYROSYLASPARTYLGLUTAMINYLISOLEUCYLMETHIONYLPROLYLLYSYLLYSINE; HEAT SHOCK PROTEIN 90; HYBRID PROTEIN; INTERLEUKIN 2; LYSYLTRYPTOPHYLPHENYLALANYLPROLYLSERYLCYSTEINYLGLUTAMINYLPHENYLALANYLLEUCYLLEUCINE; MART1 PROTEIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; PEPTIDE VACCINE; PLACEBO; PSEUDOMONAS EXOTOXIN; SURVIVIN; TRANSCRIPTION FACTOR SOX2; TUMOR ANTIGEN; TYROSYLSERYLTRYPTOPHYLMETHIONYLASPARTYLISOLEUCYLSERYLCYSTEINYLTRYPTOPHYLISOLEUCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLTYROSYLVALYLLYSYLGLYCYLLEUCYLLEUCYLALANYLLYSYLISOLEUCINE;

ABSENCE OF SIDE EFFECTS; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGENICITY; BLADDER CANCER; BREAST CANCER; CANCER IMMUNIZATION; CANCER STEM CELL; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CANCER; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FIBROSARCOMA; HUMAN; IMMUNOPATHOLOGY; IMMUNOPROPHYLAXIS; IMMUNOREGULATION; INNATE IMMUNITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNOVIAL SARCOMA; TUMOR IMMUNITY; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 63849241501     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02353.x     Document Type: Review

References (84)

1. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991 254 : 1643 7.
2. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999 10 : 281 7.
3. Andersen MH, Becker JC, Straten P. Regulators of apoptosis: Suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005 4 : 399 409.
4. Tsukahara T, Torigoe T, Tamura Y et al. Antigenic peptide vaccination: Provoking immune response and clinical benefit for cancer. Curr Immunol Rev 2008 4 : 235 41.
5. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004 10 : 909 15.
6. Tsukahara T, Kawaguchi S, Nagoya S et al. Novel approach to immunotherapy for epithelial cancers, bone and soft-tissue sarcomas. Ann Cancer Res Ther 2004 12 : 53 70.
7. Kawaguchi S, Wada T, Tsukahara T et al. A quest for therapeutic antigens in bone and soft tissue sarcoma. J Transl Med 2005 3 : 31 8.
8. Kawaguchi S, Wada T, Ida K et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005 3 : 1.
9. Tsuruma T, Hata F, Furuhata T et al. Peptide-based vaccination for colorectal cancer. Expert Opin Biol Ther 2005 5 : 799 807.
10. Tsuruma T, Iwayama Y, Ohmura T et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008 6 : 24.
11. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004 2 : 19.
12. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004 22 : 531 62.
13. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 2003 100 : 10 902 6.
14. + T cell-mediated suppression by dendritic cells. Science 2003 299 : 1033 6.
15. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol 2004 5 : 508 15.
16. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997 18 : 267 8.
17. Coulie PG, Karanikas V, Lurquin C. Cytolytic T-cell response of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002 188 : 33 42.
18. Suzuki K, Sahara H, Okada Y et al. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes. J Immunol 1999 163 : 2783 91.
19. Sahara H, Nabeta Y, Torigoe T et al. A gene encoding human gastric signet ring cell carcinoma antigen recognized by HLA-A31-restricted cytotoxic T lymphocytes. J Immunother 2002 25 : 235 42.
20. Nabeta Y, Kawaguchi S, Sahara H et al. Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci 2003 8 : 554 9.
21. Tsukahara T, Nabeta Y, Kawaguchi S et al. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 2004 64 : 5442 8.
22. Tsukahara T, Kimura S, Ichimiya S et al. Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci 2008 99 : 368 75.
23. Tsukahara T, Kawaguchi S, Torigoe T et al. HLA-A* 0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor. J Transl Med (in press).
24. Tsukahara T, Kawaguchi S, Torigoe T et al. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci 2008 99 : 368 75.
25. Hirohashi Y, Torigoe T, Maeda A et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002 8 : 1731 9.
26. Idenoue S, Hirohashi Y, Torigoe T et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005 11 : 1474 82.
27. Hariu H, Hirohashi Y, Torigoe T et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in Lung Cancer. Clin Cancer Res 2005 11 : 1000 09.
28. Kobayashi J, Torigoe T, Hirohashi Y et al. Comparative study on the immunogenicity between an HLA-A24-restrictive cytotoxic T-cell epitope derived from surviving and that from its splice variant survivin-2B in oral cancer patients. J Transl Med 2009 7 : 1.
29. Kitamura H, Torigoe T, Honma I et al. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: Implications for specific immunotherapy. Urology 2006 67 : 955 9.
30. Schmidt SM, Schag K, Muller MR et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003 102 : 571 6.
31. Sato Y, Nabeta Y, Tsukahara T et al. Detection and induction of cytotoxic T lymphocytes specific for SYT-SSX-derived peptides in HLA-A24+ patients with synovial sarcoma. J Immunol 2002 169 : 1611 18.
32. Sato Y, Sahara H, Tsukahara T et al. Improved generation of HLA class I/peptide tetramers. J Immunol Methods 2002 271 : 177 84.
33. Ida K, Kawaguchi S, Sato Y et al. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol 2004 173 : 1436 43.
34. Sato E, Torigoe T, Hirohashi Y et al. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res 2008 14 : 6916 23.
35. Inoda S, Hirohashi Y, Torigoe T et al. Cep55/c10orf3, a highly immunogenic tumor antigen derived from centrosome in the breast carcinoma. Clin Cancer Res (in press).
36. + T cell efficacy in vaccination and disease. Nat Med 2008 14 : 623 8.
37. Hofmann MA, Kors C, Andring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008 31 : 520 27.
38. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007 445 : 106 10.
39. Parmiani G, Russo V, Marrari A et al. Universal and stemness-related tumor antigens: Potential use in cancer immunotherapy. Clin Cancer Res 2007 13 : 5675 9.
40. Piccirillo SG, Reynolds BA, Zanetti N et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumor-initiating cells. Nature 2006 444 : 761 5.
41. Yagihashi A, Sato N, Torigoe T et al. Identification of the transformation-associated cell surface antigen expressed on the rat fetus-derived fibroblast. Cancer Res 1988 48 : 2798 804.
42. Konno A, Sato N, Yagihashi A et al. Heat- or stress-inducible transformation-associated cell surface antigen on the activated H-ras oncogene-transfected rat fibroblast. Cancer Res 1989 49 : 6578 82.
43. Kanki K, Torigoe T, Hirai I et al. Molecular cloning of rat NK target structure: the possibility of CD44 involvement in NK cell-mediated lysis. Microbiol Immunol 2000 44 : 1051 61.
44. Mimeault M, Hauke R, Mehta PP, Batra SK. Recent advances in cancer stem/progenitor cell research: Therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007 11 : 981 1011.
45. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003 100 : 3983 8.
46. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cell. Cancer Res 2007 67 : 1030 37.
47. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007 104 : 973 8.
48. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005 65 : 10 946 51.
49. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007 445 : 111 15.
50. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996 183 : 1797 806.
51. Zhou S, Schuetz JD, Bunting KD et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001 7 : 1028 34.
52. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentio BP. Bcrp 1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoieitic cells vivo. Proc Natl Acad Sci USA 2002 99 : 12 339 44.
53. Turnquist HR, Thomson AW. Taming the lions: Manipulating dendritic cells for use as negative cellular vaccines in organ transplantation. Curr Opin Organ Transplant 2008 13 : 350 57.
54. Hatakeyama N, Tamura Y, Sahara H et al. Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells. Exp Hematol 2006 34 : 197 207.
55. Tamura Y, Tsuboi N, Sato N, Kikuchi K. 70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity. J Immunol 1993 151 : 5516 24.
56. Takashima S, Sato N, Kishi A et al. Involvement of peptide antigens in the cytotoxicity between 70-kDa heat shock cognate protein-like molecule and CD3+, CD4-, CD8-, TCR-alpha beta- killer T cells. J Immunol 1996 157 : 3391 5.
57. Ueda G, Tamura Y, Hirai I et al. Tumor-derived heat shock protein70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity. Cancer Sci 2004 95 : 248 53.
58. Tamura Y, Sato N. Heat shock proteins: Chaperoning of innate and adaptive immunities. Jpn J Hypertherm Oncol 2003 19 : 131 9.
59. Kitamura H, Torigoe T, Honma I et al. Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus calmette-guerin immunotherapy for bladder cancer. Clin Cancer Res 2006 12 : 4641 4.
60. Tamura Y, Torigoe T, Sato N. Extracellular heat shock proteins in immune response: A guide for cross-presentation. In : Radons J, Multhoff G, eds. Heat Shock Proteins in Biology and Medicine. Kerala : Research Signpost, 2006 119 30.
61. Tamura H, Kutomi G, Oura J, Torigoe T, Sato N. Piloting of exogeneous antigen into cross-presentation pathway by heat shock proteins. In : Calderwood SK, ed. Heat Shock Proteins in Cancer. Dordrecht: : Springer, 2007 383 96.
62. Maeda H, Sahara H, Mori Y et al. Biological heterogeneity of the peptide binding motif of the 70-kDa heat shock protein by surface plasmon resonance analysis. J Biol Chem 2007 282 : 26 956 62.
63. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006 124 : 783 801.
64. Kagan JC, Su T, Horng T, Chow A, Akira S, Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon Nat Immunol 2008 9 : 361 8.
65. Watts C. Location, location, location; identifying the neighborhoods of LPS signaling. Nat Immunol 2008 9 : 343 5.
66. Matzinger P. The danger model: A renewed sense of self. Science 2002 296 : 301 5.
67. Kurotaki T, Tamura Y, Ueda G et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol 2007 179 : 1803 13.
68. Maleno I, Cabrera CM, Cabrera T et al. Distribution of HLA class I altered phenotypes in colorectal carcinomas: High frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 2004 56 : 244 53.
69. Maleno I, Lopez-Nevot MA, Seliger B, Garrido F. Low frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 in clear renal cell carcinomas. Int J Cancer 2004 109 : 636 8.
70. Kanaseki T, Blanchard N, Hammer GE, Gonzalez F, Shastri N. ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity 2006 25 : 795 806.
71. Attia P, Powell DJ, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother 2006 29 : 208 14.
72. Tukahara T, Kawaguchi S, Torigoe T et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006 97 : 1374 80.
73. Kitamura H, Honma I, Torigoe T, Asanuma H, Sato N, Tsukamoto T. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol 2007 177 : 1269 72.
74. Kikuchi F, Yamazaki K, Torigoe T et al. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer. Cancer Sci 2007 98 : 1424 30.
75. Kanaseki T, Ikeda H, Takamura Y et al. Histone deacetylation, but not hypermethylation, modifies CIITA and MHC class II gene expression in squamous cell carcinomas. J Immunol 2003 170 : 4980 85.
76. Takamura Y, Ikeda H, Kanaseki T et al. Regulation of MHC class II expression in glioma cells by class II transactivator (C IITA). Glia 2004 45 : 392 405.
77. Morimoto Y, Toyota M, Satoh A et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-γ in haematopoietic tumor cells. Br J Cancer 2004 90 : 844 52.
78. Gottlicher M, Minucci S, Zhu P et al. Valproic acid defines a novel class of HDAC inhibitors inducing defferentiation of transformed cells. EMBO J 2001 20 : 6969 78.
79. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 5 : 769 84.
80. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008 8 : 279 89.
81. Demotte N, Stroobant V, Courtoy PJ et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008 28 : 414 24.
82. Asanuma H, Torigoe T, Kamiguchi K et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005 65 : 11 018 25.
83. Yamamoto M, Torigoe T, Kamiguchi K et al. A novel isoform of TUCAN is overexpressed in human cancer tissues and suppresses both caspase-8- and caspase-9-mediated apoptosis. Cancer Res 2005 65 : 8706 14.
84. Sakaguchi A, Yamaguchi T, Nomura T, Ono M Regulatory T cell and immune tolerance. Cell 2008 133 : 775 87.